Outcome of the Board Meeting Schedule to be held on 30th March, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Asston Pharmaceuticals held a board meeting on 30th March 2026 and approved three key appointments along with scheduling an Extraordinary General Meeting. Mr. Sumit Pawar was appointed as the new Chief Financial Officer, a Commerce graduate with over 3 years of experience in finance and accounting. Mr. Yashvardhan Tupe (Mechanical Engineer with an MSc in Management) was appointed as Additional Non-Executive Director, while Mr. Sandip Sharma, a qualified Company Secretary with a Certificate of Independent Director from IICA, was appointed as Additional Non-Executive Independent Director. The board also approved the date and notice for an EGM scheduled on 28th April 2026 at 12:30 PM via video conferencing. None of the newly appointed directors are related to any existing board members.
This is a routine corporate governance update involving key managerial and board-level appointments, including filling the CFO position. Investors should watch for the EGM on 28th April 2026, which may have material business items requiring shareholder approval. The appointments strengthen the leadership and compliance functions but have no direct impact on financials or share price at this stage.